Lakefront Biotherapeutics (GLPGF) Receivables - Net (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Receivables - Net for 14 consecutive years, with $25.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Receivables - Net fell 52.7% year-over-year to $25.4 million in Q1 2026; TTM through Mar 2026 was $25.4 million, a 52.7% decrease from a year earlier, with the FY2025 full-year figure at $23.4 million, down 54.47% from the prior year.
• Receivables - Net was $25.4 million for Q1 2026 at Lakefront Biotherapeutics, up from $24.1 million in the prior quarter.
• Over five years, Receivables - Net peaked at $41.2 billion in Q4 2022 and troughed at $24.1 million in Q4 2025.
• A 5-year average of $3.2 billion and a median of $51.1 million in 2023 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net slumped 99.93% in 2023 and jumped 65.74% in 2024, its largest moves.
• Over 5 years, Receivables - Net stood at $41.2 billion in 2022, then tumbled by 99.93% to $30.6 million in 2023, then jumped by 65.74% to $50.7 million in 2024, then tumbled by 52.49% to $24.1 million in 2025, then rose by 5.59% to $25.4 million in 2026.
• The last three Receivables - Net figures came in at $25.4 million (Q1 2026), $24.1 million (Q4 2025), and $53.0 million (Q3 2025), per Business Quant data.